Alector (ALEC) announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer’s disease, AD. Alector and GSK are co-developing AL101, an investigational human monoclonal antibody designed to block and downregulate the sortilin receptor to elevate progranulin, PGRN, levels in the brain. Modest reductions in PGRN levels due to GRN gene mutations have been shown to be associated with an increased risk of developing AD. Conversely, elevated PGRN levels have been shown to be protective in animal models of AD.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALEC:
- Alector Announces Resignation of Chief Medical Officer
- Alector assumed with an Underweight at Morgan Stanley
- Cautious Outlook on Alector: Limited Prospects for Latozinemab and Financial Uncertainty Drive Sell Rating
- Alector’s Earnings Call: Progress Amid Challenges
- Promising Clinical Data and Scientific Rationale Support Alector’s Therapeutic Approach in Neurodegenerative Diseases